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Background: The aim of this study was to develop new systems for transdermal delivery of 
paeonol, in particular microemulsion gel and cubic gel formulations.
Methods: Various microemulsion vehicles were prepared using isopropyl myristate as an oil 
phase, polyoxyethylated castor oil (Cremophor® EL) as a surfactant, and polyethylene glycol 400 
as a cosurfactant. In the optimum microemulsion gel formulation, carbomer 940 was selected 
as the gel matrix, and consisted of 1% paeonol, 4% isopropyl myristate, 28% Cremophor EL/
polyethylene glycol 400 (1:1), and 67% water. The cubic gel was prepared containing 3% 
  paeonol, 30% water, and 67% glyceryl monooleate.
Results: A skin permeability test using excised rat skins indicated that both the cubic gel and 
microemulsion gel formulations had higher permeability than did the paeonol solution. An in 
vivo pharmacokinetic study done in rats showed that the relative bioavailability of the cubic gel 
and microemulsion gel was enhanced by about 1.51-fold and 1.28-fold, respectively, compared 
with orally administered paeonol suspension.
Conclusion: Both the cubic gel and microemulsion gel formulations are promising delivery 
systems to enhance the skin permeability of paeonol, in particular the cubic gel.
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Introduction
Paeonol, the active constituent of Cortex moutan, is widely used in traditional Chinese 
medicine as a pain reliever, anticoagulant, antibiotic, and antiatherosclerotic agent. 
In recent years, many studies have shown that paeonol has a number of therapeutic 
effects, including antianalgesic, antihypertensive, anticoagulant, antibacterial, 
  anti-inflammatory, immunoregulatory, antiatherosclerotic, and central nervous system 
inhibitory activities.1–3
A microemulsion is a nanosized formulation in which active drug is dispersed in 
a mixture of water, oil, and surfactant, frequently in combination with a cosurfactant, 
and is an optically clear, stable, isotropic liquid, containing particles with diameters of 
100 nm and less.4,5 Incorporation of a gel matrix into an o/w microemulsion provides 
the opportunity to obtain properties comparable with those attainable using hydrogels. 
Formulations of microemulsion gel were first reported in 1986,6,7 and since then their 
structure and physicochemical properties have been described.8–10 Microemulsion gels 
can increase the permeability of some drugs.
A cubic gel is formed spontaneously when amphiphilic lipids are placed in an 
aqueous environment. A cubic gel consists of a curved bicontinuous lipid bilayer 
and has a thermodynamically stable structure. Glyceryl monooleate/water systems International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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are an example. They can incorporate small-molecule 
drugs and large proteins,11,12 and have the ability to enhance 
permeability.13
Currently commercialized preparations of paeonol 
include a cyclodextrin injection, oral solution, and ointment.14 
Although paeonol preparations of gel and emulsion are being 
studied, combinations of paeonol with cubic gel and micro-
emulsion gel have been less widely reported. Paeonol is a 
small phenolic compound showing white crystalline needles. 
It has the characteristics of a low melting point, volatility, 
and poor water solubility. The molecular weight of paeonol 
is 166.18, and its chemical structure is 2-hydroxy-4-methoxy 
acetophenone (Figure 1). Paeonol is absorbed rapidly after 
oral administration, and its poor oral bioavailability is sug-
gested to be due to rapid and complete first-pass metabolism 
of the drug.15 Paeonol is more suitable for transdermal deliv-
ery. In order to enhance the permeability and stability of 
paeonol, the microemulsion gel and cubic gel formulations 
were selected for investigation as drug delivery systems. The 
purpose of this work was to prepare a microemulsion gel and 
cubic gel for transdermal delivery of paeonol, to study the 
skin permeability of paeonol in microemulsion gel and in 
cubic gel, and evaluate whether the microemulsion gel and 
cubic gel formulations could improve the bioavailability of 
paeonol compared with oral administration.
Materials and methods
Materials
Paeonol (99% purity) was obtained from Nanjing Qingze 
Pharmaceutical Technology Development Co Ltd   (Nanjing, 
China). Glyceryl monooleate (.99%) was supplied by 
Danisco (Copenhagen, Denmark). Carbomer 940 was 
purchased from Shanghai Xietai Chem Co Ltd (Shanghai, 
China). Transcutol® P and Labrafac® were kindly donated 
by Gattefosse (St Priest, France). Cremophor® EL (Crel) 
and Cremophor® RH 40 (CRH40) were donated by BASF 
(Ludwigshafen, Germany). Isopropyl myristate, oleic acid, 
ethyl oleate, propylene glycol, castor oil, ethanol, p-octy 
polyethylene glycol phenylether, polyethylene glycol 400, 
and Tween80 were purchased from Sinopharm Chemical 
Reagent Corporation (Shanghai, China). Soybean oil was 
obtained from Tieling North Asia Medicinal Oil Co Ltd 
(Tieling, China).
Pseudoternary diagrams
To determine the composition of microemulsions, pseudoternary 
phase diagrams were constructed by titrating a series of oil, 
surfactant, and cosurfactant with water mixtures at ambient 
temperature (25°C). Surfactants and cosurfactants were 
blended at different mass ratios (1: 2, 1:1, 2:1, 4:1), then each 
surfactant-cosurfactant mixture was mixed with oil, and the 
ratio of oil to the surfactant and cosurfactant mixture was 
varied at 9:1, 8:2, 7:3, 6:4, 5:5, 4:6, 3:7, 2:8, and 1:9 (w/w). 
Water was added drop by drop to the mixture under vigorous 
stirring. During titration, the isotropic, liquid crystalline, 
and coarse emulsion phases were observed with turbidity-
to-transparency or transparency-to-turbidity transitions 
occurring. Clear and transparent formulations were indicative 
of a stable microemulsion, and their compositions were 
recorded. The physical states were marked on a pseudoternary 
phase diagram representing the surfactant and cosurfactant 
mixture, with the other two axes representing oil and water.
Preparation of microemulsions
Based on the phase diagram, different formulae were selected 
from the microemulsion region (Table 1). Exactly 1% w/w of 
paeonol was dissolved in the oil, surfactant, and   cosurfactant 
mixtures, and water was added drop by drop under   magnetic 
stirring at room temperature. The control solution was 
  prepared by dissolving paeonol in phosphate-buffered saline 
at pH 7.4 to achieve a concentration 400 µg/mL and then 
stirring the solution at 1000 rpm.
Microemulsion droplet size and morphology 
analysis
Microemulsion particle size was determined using photo-
correlation spectroscopy (Malvern, Worcestershire, UK) at 
OH
O
O
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25°C. Droplet morphology was observed using transmission 
electron microscopy (TEM) (JEM-2010; JEOL, Tokyo, 
Japan). One drop of each diluted sample was deposited on 
a film-coated 200-mesh copper specimen grid and allowed 
to stand for 10 minutes, after which any excess fluid was 
removed with filter paper. The grid was then stained with 
one drop of 3% phosphotungstic acid and dried for 5 minutes 
before examination with an electron microscope.
Preparation of microemulsion gel
Carbomer 940 0.5%–2.0% (w/w) swelled after addition of 
water, and pH was adjusted using triethanolamine 0.5%–2.0% 
(w/w). The oily solution was prepared by mixing Crel, poly-
ethylene glycol 400, isopropyl myristate, and paeonol, and 
was then swelled with carbomer 940 and vigorously mixed 
until a homogeneous dispersion was obtained.
Preparation of cubic gel
Paeonol 3% w/w was mixed with melted glyceryl monooleate 
in glass vials at 42°C until completely dissolved or dispersed. 
Distilled water preheated to 42°C was incorporated gradually 
into the mixture at 30% w/w. Samples were kept at room 
temperature in the dark for 3 days.
In vitro permeability studies
The abdominal skins of male Wistar rats weighing 220 ± 20 g 
were used for the permeability experiments, which were 
carried out in accordance with the guidelines of the animal 
ethics committee at Shanghai Jiao Tong University. The 
abdominal skin was carefully removed leaving the fat tissue 
behind. The skin was examined under a magnifying lens for 
damage or disease, and any skin with a disrupted barrier was 
excluded. Freshly prepared abdominal skin was used in the 
diffusion experiments. Vertical Franz-type diffusion cells 
(Shanghai Institute of Organic Chemistry) with a diffusional 
surface area of 0.754 cm2 and a 5 mL cell volume were used 
to study the permeability of the microemulsion gel and cubic 
gel formulations. The skin was placed between the donor and 
receptor compartments of the cells, with the stratum corneum 
side facing the donor compartment. The receiver compartment 
was filled with 5 mL of phosphate-buffered saline at pH 
7.4, with temperature maintained at 32°C ± 0.5°C using a 
thermostatic water bath (Variomag, Munich,   Germany) and 
stirring at 600 rpm throughout the experiment. Microemulsion 
1 mL and gel 1 g samples containing   paeonol were placed into 
each donor compartment, and 0.2 mL of the receptor solution 
was withdrawn at predetermined time points (hours 1, 2, 3, 
4, 5, 6, 7, and 8), then replaced with an equivalent volume of 
phosphate-buffered saline to maintained a constant volume. 
The samples collected were filtered through a 0.45 µm mem-
brane and assayed by high-pressure liquid chromatography. 
The cumulative amount of paeonol that permeated through 
the rat skins was calculated using the equation:
 C nc = Cn + (0.2/5) × ΣCp
 Q  = Cnc × 5/0.754
where Q was the accumulated amount at a given time t, Cn 
was the drug concentration of the n sample at the sampling 
time, ΣCp was the sum of the drug concentration of all 
the n-1 samples measured, and Cnc was the transdermal 
concentration after correction. The cumulative amount (Q) 
of paeonol permeated was plotted as a function of time (t) 
for each formulation. The skin permeation rate at steady-
state (Jss, µg/cm2/hour) was calculated from the slope of the 
linear portion of the plots of Q versus time. The permeability 
coefficient was calculated by dividing Jss by the initial 
concentration of drug in the donor cell (C0):16
  permeability coefficient = Jss/C0
Table 1 compositions of various topical formulations for paeonol delivery
Components Formulations
A B C D E F Cubic gel MG
ethyl oleate 7
Isopropyl myristate 4 4 4 7 10 4
crel:Peg400 = 1:1 28 39 50 28 28 28 28
Water 67 56 45 64 61 64 30 65
carbomer 940 1
Triethanolamine 1
gMO 67
Paeonol 1 1 1 1 1 1 3 1
Abbreviations: crel, cremophor® eL; Peg 400, polyethylene glycol; gMO, glyceryl monooleate; Mg, microemulsion gel.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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The penetration-enhancing effect of paeonol was calculated 
in terms of the enhancement ratio, and was calculated using 
the following equation:17
  enhancement ratio = Kp/K0
where Kp is the respective formulation and K0 represents the 
control solution.
In vivo permeability studies
Male Wistar rats weighing 200–230 g were obtained from the 
Animal Center of Shanghai Jiao Tong University, and fasted 
overnight with free access to water before drug administration. 
Hairs at the abdominal site were shaved off and the skin area 
washed with distilled water the day before the experiment. 
Cubic gel and microemulsion gel (30 mg/kg) were applied 
on the skin surface (7.9 cm2), which was then bound with 
gauze. Blood samples (0.25 mL) were collected at hours 0, 
0.5, 1.0, 2.0, 4.0, 6.0, 8.0, 10.0, and 12.0 after transdermal 
administration. For the oral pharmacokinetic studies, paeonol 
was suspended in 0.5% sodium carboxymethyl cellulose and 
administered (30 mg/kg) as the control. Blood samples were 
collected from the jugular vein at 0, 0.08, 0.25, 0.5, 0.75, 1.0, 
1.5, 2.0, 3.0, 4.0, 6.0, 8.0, and 12.0 hours after dosing.
All collected samples were immediately centrifuged at 
4000 rpm for 10 minutes. Plasma 0.1 mL was added to cin-
namic acid 10 µL and vortex-mixed with acetonitrile 2 mL 
for 1 minute and centrifuged at 10,000 rpm for 10 minutes. 
The supernatant was transferred to a clean test tube and 
evaporated to dryness at 25°C under a stream of nitrogen. 
The residue was dissolved in methanol 1 mL, and 20 µL of 
the sample solution was injected into the high-pressure liquid 
chromatography system.
Analysis of paeonol
Paeonol was analyzed using a reversed phase high-pressure 
liquid chromatography system. The chromatographic system 
consisted of a Waters 717 Plus autosampler (Waters, Milford, 
MA) and a Waters 2487 dual λ absorbance detector equipped 
with a prepacked Hypersil ODS column (150 mm × 4.6 mm, 
5 µm, Dalian Elite Analytical Instruments Co Ltd, Dalian, 
China). The mobile phase for analysis of paeonol consisted of 
methanol, water, and acetic acid (53:47:0.01, v/v). The eluent 
was pumped at a flow rate of 1.0 mL/min. The detector wave-
length was set at 274 nm. The injection volume was 20 µL.
statistical analysis
All skin permeability experiments were repeated three times, 
and the results expressed as means ± standard deviation. 
Statistical significance was assessed using the Student’s t-test 
for multiple comparison. A P value , 0.05 was considered 
to indicate statistical significance.
Results and discussion
Pseudoternary diagrams
Pseudoternary phase diagrams of the system containing 
isopropyl myristate, Crel, polyethylene glycol 400, and 
water are shown in Figure 2. The black areas indicate the 
clear o/w microemulsion region. The microemulsion domain 
was determined by visual inspection for clarity and fluidity 
as well as through a cross polarizer for the absence of a 
liquid crystalline phase. The rest of the region in the phase 
diagram represents turbid and conventional emulsions based 
on visual observation. No liquid crystalline structure was 
observed using the cross polarizer. Phase studies were used 
to estimate the effect of surfactant/cosurfactant (S/Cos) in 
stable o/w microemulsion regions. As shown in Figure 2, the 
monophasic zone of o/w microemulsion reaches a maximum 
at a S/Cos of 1.
characteristics and physicochemical 
properties of the microemulsions
The particle size of the microemulsion was one of the most 
important properties. All the microemulsions (A–F) had 
small average droplet diameters of 27–60 nm. As a result, 
the droplet size of formulation A was 39.80 ± 4.6 nm. The 
morphology of microemulsion formulation A was character-
ized using transmission electron microscopy (Figure 3), and 
showed a spherical shape and uniform droplet size. Samples 
were diluted with distilled water before testing to avoid 
multiscattering phenomena. After that, the droplet size of 
the diluted microemulsion was not significantly changed. 
The mean particle size remained consistent for 3 months at 
room temperature.
Preparation of gels
In this work, carbomer 940 was added to vehicle A to prepare 
the microemulsion gel. We found that carbomer 940 could 
increase the viscosity of the microemulsion, maintain the 
microemulsion structure, and provide a good matrix for the 
microemulsion gel.
Microemulsion gel containing 0.5% carbomer 940 had 
relatively high fluidity. The viscosity of the microemulsion 
gel increased with increasing concentrations of carbomer 
940. However, 2% carbomer 940 resulted in excessive micro-
emulsion gel viscosity. Microemulsion gel containing 1% 
carbomer 940 has suitable viscosity for topical application.18 International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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As far as we know, glyceryl monooleate, monoolein, 
phosphatidylethanolamine, phospholipids, and PEGylated 
phospholipids19–22 are used to form the cubic phases. In this 
study, glyceryl monooleate was selected to prepare the cubic 
gel. After 3 days of equilibration, the cubic gel developed into 
glass-clear, nonbirefingent, and stiff cubic phase forms, and 
had greater transparency than the microemulsion gel. Both 
microemulsion gel with 1% carbomer 940 and the cubic 
gel were stable at 30°C. No changes in phase separation 
or paeonol degradation were observed over 3 months. The 
centrifuge test showed that all the gels still maintained good 
physical stability.
In vitro permeability studies
In vitro skin studies were performed to compare drug 
  permeability from six different microemulsion formulations, 
and the percutaneous parameters, including permeability 
coefficient and enhancement ratio, were calculated following 
zero order release kinetics. A steady increase in the amount 
of permeated drug in the receptor compartment with time 
was observed. The permeation coefficient ranged from 
1.68 ± 0.31 to 6.53 ± 1.08 cm/hour × 10–3, and the highest 
value was for vehicle A and the lowest was for vehicle C, so 
vehicle A was selected to prepare the microemulsion gel.
As shown in Table 2, the permeability coefficient of the 
microemulsion gel was 5.88 ± 0.28 cm/hour × 10–3, which was 
less than that for vehicle A. Vehicle A and the microemulsion 
gel produced a significantly higher permeability coefficient, 
ie, a 2.13-fold and 1.92-fold increase, respectively, compared 
with the control solution. Peltola et al reported that carbomer 
940 might influence the permeability of estradiol. The perme-
ability of paeonol decreased with the addition of carbomer 
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Figure 2 Pseudoternary phase diagrams of microemulsion composed of isopropyl myristate, surfactant (crel), cosurfactant (Peg400) and water.
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940 to the microemulsion, possibly because of increased 
viscosity and the changing structure of the vehicle.23,24 In 
this work, the addition of 1% carbomer 940 had the same 
influence on the permeability of paeonol.
Figure 4 shows the permeability of paeonol through rat 
skin. The cumulative amount of paeonol in the cubic gel was 
significantly higher (P , 0.05) than that of paeonol in the 
microemulsion gel and control solution. With a permeability 
coefficient of 8.34 ± 0.49 cm/hour × 10–3, cubic gel was a 
better carrier for transdermal delivery of paeonol than the 
microemulsion gel and control solution. There may be two 
factors accounting for this. Firstly, the content of paeonol in 
the cubic gel was higher than in the microemulsion gel, which 
means that the cubic gel had better drug solubility, which 
could contribute to improved absorption of the drug.25,26 
Secondly, the structure of the cubic gel might be better than 
that of the microemulsion gel for drug delivery. The struc-
ture of the cubic phase is unique and consists of a curved 
bicontinuous lipid bilayer, which resembles the structure of 
lipid membranes found in nature,27,28 so might result in good 
adhesiveness to the skin and good delivery of the drug.
In vivo permeability studies
The mean plasma concentration versus time profiles for 
paeonol after oral and transdermal administration are shown 
in Figure 5, and the mean pharmacokinetic parameters 
  calculated by DAS2.1.1 are given in Table 3. These show that 
paeonol is rapidly absorbed, with a maximum concentration 
of 1.64 ± 0.14 µg/mL at 0.25 ± 0.06 hours after a single oral 
dose. The time taken to reach maximum concentration of 
paeonol in the cubic gel and microemulsion gel was 3 hours 
and 2 hours, respectively, after transdermal administration. 
This result is similar to the phenomenon reported by Sun 
et al, who detected the maximum concentration at 5 minutes 
after an oral dose.29 This was due to dermal accumulation of 
paeonol because of the barrier properties of skin. An increase 
in the area under the concentration-time curve (AUC) for 
paeonol was observed when the cubic gel and microemulsion 
gel were studied. The relative bioavailability of paeonol in 
cubic gel and microemulsion gel was 1.51 and 1.28 times 
higher, respectively, than after oral administration of the 
drug. Mean residence times following a transdermal dose 
of cubic gel and microemulsion gel were 5.63 ± 1.32 hours 
and 5.62 ± 1.11 hours, respectively, which were higher than 
that for paeonol suspension.
Compared with oral administration, transdermal 
administration had a longer time to reach maximum plasma 
concentration, a lower maximum plasma concentration, 
higher AUC, and higher mean residence time, because of 
avoidance of the substantial amount of hepatic first-pass 
metabolism associated with oral administration.
The mechanism for the enhanced transdermal penetration 
of microemulsion gel and cubic gel for paeonol might be 
attributable to several factors. Firstly, the high concentration 
(1%) of paeonol in the microemulsions resulted in high 
concentration gradients, which might be the main mechanism 
Table 2 Permeability coefficient and enhancement ratio of paeonol 
through excised rat skin from different vehicles
Vehicle Kp (cm/hour) × 10–3 Enhancement ratio
control 3.06 ± 0.10
A 6.53 ± 1.09* 2.13
Mg 5.88 ± 0.28* 1.92
cubic gel 8.34 ± 0.49** 2.73
Notes: *P , 0.05, **P , 0.01, compared with control; each value represents means 
± standard deviation of at least three experiments.
Abbreviation: Mg, microemulsion gel.
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by which paeonol in a microemulsion gel penetrates 
the skin.26
Microemulsions could act as drug reservoirs whereby 
drug is released from an inner phase to an outer phase and 
then into the skin.24 Secondly, due to the small droplet size, 
droplets settling in close contact with the skin might penetrate 
the skin surface.24
In the case of cubic phase gel, glyceryl monooleate could 
intercalate with the extracellular lipid matrix of the skin, and 
disrupt its well organized compact structure.30 Some studies 
have reported that enhanced transdermal delivery of drugs 
may depend on a disordered state, or depend on a different 
order of lipids, given that intercellular lipids can rearrange 
into a cubic phase under specific circumstances.31
In both the in vitro permeability and in vivo bioavailability 
experiments, a correlation was obtained between the 
  outcomes of the in vitro permeability model and the in vivo 
bioavailability data. The in vitro permeability experiments 
indicate that the cubic gel formulation yielded the highest 
permeability coefficient of the three tested formulations, and 
this was also the case in the in vivo assessment model, with 
the AUC of the cubic gel formulation being higher than that 
of the other two formulations.
Conclusion
In this study, novel microemulsion gel and cubic gel formu-
lations for transdermal delivery of paeonol were developed. 
Our results indicate that both the cubic gel and microemulsion 
gel formulations had a higher permeability coefficient than 
the control group. An in vivo pharmacokinetic study in rats 
showed that the relative bioavailability of the cubic gel and 
the microemulsion gel was enhanced by about 1.51-fold and 
1.28-fold, respectively, compared with oral administration 
of paeonol suspension. These data collectively support the 
hypothesis that cubic gel and microemulsion gel formulations 
are promising delivery systems to enhance the skin perme-
ability of paeonol, especially the cubic gel.
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Figure 5 Plasma concentration of paeonol following oral and transdermal administration to rats.
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Table  3  Pharmacokinetic  parameters  obtained  after  oral  and 
transdermal administration of paeonol in rats
Parameter Transdermal administration Oral  
administration Cubic gel MG
cmax (µg/mL) 0.68 ± 0.10* 0.72 ± 0.15* 1.64 ± 0.14
Tmax (hours) 3.00 ± 0.16** 2.00 ± 0.32** 0.25 ± 0.06
T1/2 (hours) 2.58 ± 0.13 3.45 ± 0.49** 1.54 ± 0.29
AUc (µg/mL/hour) 4.60 ± 0.54* 3.89 ± 1.01 (ns) 3.04 ± 0.42
MrT (hours) 5.63 ± 1.32* 5.62 ± 1.11* 1.64 ± 0.33
Notes: Data are expressed as the means ± standard deviation for six rats; *P , 0.05, 
compared with oral administration; **P , 0.01, compared with oral administration.
Abbreviations: AUc, area under the concentration–time curve; Mg, microemulsion 
gel; cmax, maximum concentration; ns, not significant; Tmax, time to reach maximum 
concentration; T1/2, elimination half-life; MrT, mean residence time.International Journal of Nanomedicine
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